Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05730244

A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor

The goal of this clinical trial is to establish the efficacy of Cassia alata extract as a cream form in treating tinea versicolor (liver spots/shifting clouds). The main questions the study aims to answer are:• Does the use of this extract help resolve tinea versicolor better than no treatment? Does the use of this cream have significant side effects i.e, is it safe? Participants will be asked to treat a designated area while leaving additional areas untreated. 1-2 finger tip units of cream will be applied to the treatment site twice daily at least 8 hours apart. Participants will attend the trial clinic every 4 weeks for 12 weeks.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

University of the West Indies, Mona

Kingston, Other, 007, Jamaica

Location status: Recruiting

Location contact

Chelsea Roye, MBBS

SUB_INVESTIGATOR

Jheanelle Foster, MBBS

SUB_INVESTIGATOR

Marvin Reid, MB BS

CONTACT

[email protected]

8769271884

About this study

Tinea (pityriasis) versicolor is a common superficial fungal infection. A variety of topical antifungals are used in its treatment. In Jamaica, many people use crushed leaves of the Cassia alata plant (Senna alata) as a traditional remedy. Rare investigators have described its activity against the causative fungus, Malassezia spp. Aim: We wish to confirm the efficacy of the extract, devise dosing regimen, document potential side effects Study Design/Methodology: A single-arm arm no-treatment self-controlled trial pilot study evaluating the clinical efficacy and safety profile of 20% Cassia alata cream against tinea versicolor. Therapeutic efficacy reported as clinical and microbiological resolution of tinea versicolor in treated area will be assessed and compared with non-treated areas. Side effects and ease of use will be evaluated for and reported. Assessment will occur at baseline, 1 week, 4 weeks, 8 weeks and 12 weeks. Demographics will be tabulated and categorical variables generated. Associations of the presence/absence of these variables within both groups will be evaluated for using chi-squared tests. Results will be analyzed using SPSS version 26. Location: Dermatology Division (Room 13 Dept of Pathology) at University Hospital of the West Indies. Data Storage: Unique study ID, locked room and password protected computer belonging to the principal investigator. Only approved study investigators will have access. Time frame: 24 months months Confidentiality Statement: This study requires approval by the Ethics Committee, will require an informed consent and will comply with ethical rules governing research using human subjects, patient confidentiality and non-coercion as detailed within the proposal.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18-89 of either sex
  • Clinical features suggestive of tinea versicolor AND Microscopic confirmation using skin scraping stains with chlorazol black preparation AND/OR Wood's lamp fluorescence
  • No treatment for versicolor in the preceding 4 weeks
  • No contraindications to the application of C.alata cream including
  • No history of allergy to C. alata
  • No history of preservative allergy

Exclusion criteria

  • Age <18 or >89 years
  • Pregnant females
  • History of hypersensitivity to C. alata or preservative
  • Treatment within 4 weeks prior to enrollment
  • Lesions which do not meet the diagnostic criteria of tinea versicolor

Treatment and study plan

20% Cassia alata cream

Drug

Thin layer of cassia alata cream to cover treatment area. 1 finger tip unit will cover roughly 4 x 4 inch area. Number of FTU determined by investigators depending on rough size of area to be treated

Primary outcomes

  1. Lesion Clearance

    Time frame: 12 weeks

    Proportion of participants with no visible lesions on which treatment applied. We will visually compare to baseline images and untreated skin

  2. Fungal load

    Time frame: 12 weeks

    Change in the fungal load on skin scraping. We will looks for decrease in positivity and density in treated skin compared with baseline and untreated control skin

Secondary outcomes

  1. Local skin reactions

    Time frame: 12 weeks

    Proportion of participants with new skin reactions (burning, pain, pruritus, blisters, color change)

Study contacts

Contact information is provided by the study sponsor or research team.

Marvin Reid, MB Bs PhD

CONTACT

[email protected]

8763812939

Sponsors and collaborators

Lead sponsor

The University of The West Indies

Other

Registry information

Official study title

A Single Arm No-treatment Self-controlled Trial Pilot Study Evaluating the Clinical Efficacy and Safety Profile of 20% Cassia Alata Cream Against Tinea Versicolor

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 15, 2023
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.